AMYLIN PHARMACEUTICALS, LLC

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 9246
 
  
 
C07K PEPTIDES 4132
 
  
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 346
 
  
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 194
 
  
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 1166

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

  • No Recent Publications to Display

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9884092 Methods for treating diabetes and reducing body weightMay 31, 16Feb 06, 18[A61K, C07K]
9238076 Polymer-based sustained release deviceJan 16, 13Jan 19, 16[A61K]
9161953 GLP-1 receptor agonists for islet cell transplantationDec 20, 11Oct 20, 15[A61K, A01N]
8951962 Modified exendins and exendin agonistsMay 17, 13Feb 10, 15[A61K, C12N, A61P, C07K]
8906851 Method for treating diabetesDec 07, 12Dec 09, 14[A61K, A61P, C07K]
8895498 GIP and exendin hybrid polypeptidesAug 22, 12Nov 25, 14[A61K, A61P, C07K]
8288338 Exendin and exendin agonists for eating disordersApr 23, 10Oct 16, 12[A61K]

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2016/0361,390 GLP-1 RECEPTOR AGONIST COMPOUNDS FOR OBSTRUCTIVE SLEEP APNEAAbandonedAug 26, 16Dec 15, 16[A61K]
2016/0346,357 SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS CARRIERSAbandonedAug 11, 16Dec 01, 16[A61K]
2016/0120,950 Pharmaceutical Formulations Comprising Incretin Mimetic Peptide and Aprotic Polar SolventAbandonedOct 30, 15May 05, 16[A61K]
2015/0258,177 GLP-1 RECEPTOR AGONIST COMPOUNDS FOR OBSTRUCTIVE SLEEP APNEAAbandonedJun 02, 15Sep 17, 15[A61K]
2015/0238,568 EXENDINS TO LOWER CHOLESTEROL AND TRIGLYCERIDESAbandonedMay 13, 15Aug 27, 15[A61K]
2015/0231,204 PANCREATIC POLYPEPTIDE FAMILY MOTIFS, POLYPEPTIDES AND METHODS COMPRISING THE SAMEAbandonedNov 12, 14Aug 20, 15[A61K]
2015/0174,209 INSULIN-PRAMLINTIDE COMPOSITIONS AND METHODS FOR MAKING AND USING THEMAbandonedMay 24, 13Jun 25, 15[A61K, G06F, A61M]
2015/0157,725 TRANSMUCOSAL DELIVERY OF PEPTIDES AND PROTEINSAbandonedDec 15, 14Jun 11, 15[A61K]
2015/0152,158 METHODS TO RESTORE GLYCEMIC CONTROLAbandonedFeb 10, 15Jun 04, 15[C07K]
2015/0150,948 METHODS FOR TREATING DIABETES AND REDUCING BODY WEIGHTAbandonedNov 25, 14Jun 04, 15[A61K]
2015/0111,824 Pharmaceutical Formulations Comprising Incretin Mimetic Peptide and Aprotic Polar SolventAbandonedOct 28, 14Apr 23, 15[A61K]
2015/0080,307 EXENDINS AND EXENDIN AGONIST ANALOGS TO REGULATE GASTROINTESTINAL MOTILITYAbandonedNov 21, 14Mar 19, 15[C07K]
2015/0080,308 Formulations and Uses of Exendins and Exendin Agonist AnalogsAbandonedNov 25, 14Mar 19, 15[A61K, C07K]
2015/0056,285 SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS CARRIERSAbandonedOct 27, 14Feb 26, 15[A61K]
2014/0371,148 PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF USING SAMEAbandonedJun 18, 14Dec 18, 14[A61K]
2014/0249,076 AMYLIN-CALCITONIN CHIMERIC PEPTIDES CONJUGATED TO DURATION ENHANCING MOIETIESAbandonedOct 17, 12Sep 04, 14[A61K]
2014/0249,077 GEL COMPOSITIONSAbandonedJun 08, 12Sep 04, 14[A61K]
2014/0220,134 METHOD FOR TREATING DIABETES WITH EXTENDED RELEASE FORMULATION OF GLP-1 RECEPTOR AGONISTSAbandonedJun 21, 12Aug 07, 14[A61K]
2014/0221,282 LONG DURATION DUAL HORMONE CONJUGATESAbandonedMay 24, 12Aug 07, 14[A61K]
2014/0221,287 Amylin Peptides and Derivatives and Uses ThereofAbandonedMay 24, 12Aug 07, 14[C07K]

View all patents..

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.